The Greater Cannabis Company, Inc. (GCAN)
Oxford Ledge is still expanding full research coverage of GCAN. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
The company develops cannabinoid therapeutics for neuropsychiatric disorders, having recently completed preclinical studies and obtained approval for Phase II clinical trials.
SEC filings
- 8-K Entry into material agreement; 5.01; Departure/election of directors or officers; Financial statements and exhibits 2026-07-06
- 10-Q Quarterly financial report (unaudited) 2026-05-13
- 10-K Annual financial report with audited statements 2026-03-31
- 10-Q Quarterly financial report (unaudited) 2025-11-12
- 8-K Amendments to articles or bylaws; Other material event; Financial statements and exhibits 2025-10-27
Source: SEC EDGAR.
Insider activity
3 recent insider (SEC Form 4) filings on record for GCAN. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open GCAN in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.